Morgan Stanley
OKUR

Morgan Stanley’s OnKure Therapeutics OKUR Stock Holding History

Morgan Stanley’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.7K Buy
21,858
+7,531
+53% +$32.3K ﹤0.01% 6253
2026
Q1 		$59.3K Sell
14,327
-10,635
-43% -$32.8K ﹤0.01% 6356
2025
Q4 		$72.4K Buy
24,962
+7,748
+45% +$23.2K ﹤0.01% 6314
2025
Q3 		$47.3K Buy
17,214
+513
+3% +$1.27K ﹤0.01% 6420
2025
Q2 		$39.9K Buy
16,701
+14,823
+789% +$38.9K ﹤0.01% 6428
2025
Q1 		$8.08K Buy
1,878
+946
+102% +$5.32K ﹤0.01% 6866
2024
Q4 		$8.02K Sell
932
-5,520
-86% -$83.6K ﹤0.01% 6877
2024
Q3 		$110K Sell
6,452
-13,400
-67% -$198K ﹤0.01% 5972
2024
Q2 		$300K Sell
19,852
-2,864
-13% -$48.6K ﹤0.01% 5503
2024
Q1 		$377K Buy
22,716
+10,223
+82% +$169K ﹤0.01% 5435
2023
Q4 		$200K Buy
12,493
+9,261
+287% +$577K ﹤0.01% 5703
2023
Q3 		$246K Sell
3,232
-344
-10% -$23.4K ﹤0.01% 5493
2023
Q2 		$235K Sell
3,576
-657
-16% -$52.9K ﹤0.01% 5579
2023
Q1 		$253K Buy
4,233
+276
+7% +$10K ﹤0.01% 5598
2022
Q4 		$92.2K Sell
3,957
-32
-0.8% -$848 ﹤0.01% 6012
2022
Q3 		$134K Buy
3,989
+1,939
+95% +$63.7K ﹤0.01% 5928
2022
Q2 		$54K Buy
2,050
+1,509
+279% +$35.1K ﹤0.01% 6575
2022
Q1 		$16K Sell
541
-174
-24% -$9.74K ﹤0.01% 7242
2021
Q4 		$61K Buy
715
+299
+72% +$22K ﹤0.01% 6721
2021
Q3 		$30K Sell
416
-2,703
-87% -$229K ﹤0.01% 6930
2021
Q2 		$291K Buy
+3,119
New +$348K ﹤0.01% 5831

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's OKUR Position: Q2 2026 in Review

Morgan Stanley increased its OnKure Therapeutics (OKUR) stake by 53% in Q2 2026, buying an estimated $32.3K and bringing the position to 21,858 shares worth $99.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6253.

Morgan Stanley first reported a position in OKUR in Q2 2021 and has held it in 21 quarters since. The position peaked at $377K in Q1 2024. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Morgan Stanley held 21,858 shares of OnKure Therapeutics worth $99.7K as of Q2 2026.
  • Morgan Stanley bought 7,531 OnKure Therapeutics shares in Q2 2026, an estimated $32.3K.
  • OnKure Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6253 holding.
  • Morgan Stanley first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Morgan Stanley's OnKure Therapeutics position peaked at $377K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.